Does Novavax Have What It Takes to Win the COVID-19 Vaccine Race?
Novavax (NASDAQ: NVAX) is developing a COVID-19 vaccine candidate, and recent spikes in its stock price and trading volume indicate that investors suspect such a treatment could give the company another chance at life.
Novavax is far from a healthy business, however. The company's vaccine trials in 2016 and 2019 ended in embarrassing and costly late-stage failures due to a lack of clinical efficacy, and it's never successfully brought a product to market.
Image source: Getty Images.
Source Fool.com
